Primary candidates for GLP-1 therapy include: Patients with type 2 diabetes and inadequate glycemic control despite metformin therapy Individuals with type 2 diabetes and established atherosclerotic cardiovascular disease Patients with type 2 diabetes and multiple cardiovascular risk factors (hypertension, dyslipidemia, obesity) Adults with obesity (BMI 30 kg/m) or overweight (BMI 27 kg/m) with weight-related comorbidities Patients with metabolic syndrome who have not achieved adequate risk factor control with lifestyle modification For patients with dyslipidemia, GLP-1 agents may be particularly valuable when combined with statin therapy in those who have not reached LDL-C goals or who have persistent hypertriglyceridemia despite statin treatment
Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies
Women should not take GLP-1s or other weight loss medications while pregnant, breastfeeding, or trying to conceive
Plastic Surgery is elective, and the body should be optimized to ensure the smoothest surgery and best healing before proceeding
Retatrutide is a triple agonist (GLP-1, GIP, and glucagon receptors), while semaglutide (Ozempic, Wegovy) targets only GLP-1
Is the 4mg maintenance dose effective enough for weight loss
)
